Figure S3 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Dongshi Chen,Kaylee Ermine,Yi-Jun Wang,Xiaojun Chen,Xinyan Lu,Peng Wang,Donna B. Stolz,Jian Yu,Lin Zhang

DOI: https://doi.org/10.1158/1535-7163.25337719.v1

2024-01-01

Abstract:Figure S3. 5-FU and other antimetabolites induced necroptosis in p53-WT CRC cells expressing RIP3.

What problem does this paper attempt to address?

Figure S4 from PUMA/RIP3 Mediates Chemotherapy Response via Necroptosis and Local Immune Activation in Colorectal Cancer

Dongshi Chen,Kaylee Ermine,Yi-Jun Wang,Xiaojun Chen,Xinyan Lu,Peng Wang,Donna Beer-Stolz,Jian Yu,Lin Zhang

DOI: https://doi.org/10.1158/1535-7163.25337716

2024-01-01

Abstract:Figure S4. Knockout or knockdown of RIP3, but not RIP1, suppressed necroptosis induced by 5-FU and other antimetabolites.
Figure S8 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Dongshi Chen,Kaylee Ermine,Yi-Jun Wang,Xiaojun Chen,Xinyan Lu,Peng Wang,Donna Beer-Stolz,Jian Yu,Lin Zhang

DOI: https://doi.org/10.1158/1535-7163.25337704

2024-01-01

Abstract:Figure S8. 5-FU-induced cell-surface translocation of calreticulin and DC phagocytosis of CRC cells are mediated by p53/PUMA/RIP3-dependent necroptosis.
Figure S5 from PUMA/RIP3 Mediates Chemotherapy Response via Necroptosis and Local Immune Activation in Colorectal Cancer

Dongshi Chen,Kaylee Ermine,Yi-Jun Wang,Xiaojun Chen,Xinyan Lu,Peng Wang,Donna Beer-Stolz,Jian Yu,Lin Zhang

DOI: https://doi.org/10.1158/1535-7163.25337713.v1

2024-01-01

Abstract:Figure S5. PUMA was induced by p53 and required for necroptosis induction in LoVo cells treated with antimetabolites.
Figure S1 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Dongshi Chen,Kaylee Ermine,Yi-Jun Wang,Xiaojun Chen,Xinyan Lu,Peng Wang,Donna Beer-Stolz,Jian Yu,Lin Zhang

DOI: https://doi.org/10.1158/1535-7163.25337725

2024-01-01

Abstract:Figure S1. No association was found between RIP1 and MLKL expression and CRC patient survival.
Figure S2 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Dongshi Chen,Kaylee Ermine,Yi-Jun Wang,Xiaojun Chen,Xinyan Lu,Peng Wang,Donna B. Stolz,Jian Yu,Lin Zhang

DOI: https://doi.org/10.1158/1535-7163.25337722.v1

2024-01-01

Abstract:Figure S2. Analysis of 30 anticancer drugs revealed that 5-FU and Gemcitabine induced necroptosis in LoVo cells.
Table S1 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Dongshi Chen,Kaylee Ermine,Yi-Jun Wang,Xiaojun Chen,Xinyan Lu,Peng Wang,Donna B. Stolz,Jian Yu,Lin Zhang

DOI: https://doi.org/10.1158/1535-7163.25337698

2024-01-01

Abstract:Table S1. Key reagents used in the experiments described in this manuscript are listed.
Table S2 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Dongshi Chen,Kaylee Ermine,Yi-Jun Wang,Xiaojun Chen,Xinyan Lu,Peng Wang,Donna Beer-Stolz,Jian Yu,Lin Zhang

DOI: https://doi.org/10.1158/1535-7163.25337695

2024-01-01

Abstract:Table S2. PCR primers used in the experiments described in this manuscript are listed.
Abstract 2534: Targeting defective necroptosis in colorectal cancer to overcome therapeutic resistance

Kaylee Ermine,Dongshi Chen,Xinyan Lu,Jian Yu,Lin Zhang

DOI: https://doi.org/10.1158/1538-7445.am2023-2534

IF: 11.2

2023-04-04

Cancer Research

Abstract:Abstract Colorectal cancer (CRC) is a leading cause of cancer related deaths in the United States. CRC patients are often treated with the chemotherapeutic drug 5-fluorouracil (5-FU), but resistance often occurs. It is well-established that 5-FU induces apoptosis in cancer cells, but apoptosis inhibition does not block the anticancer effect of 5-FU, suggesting a role of non-apoptotic cell death. Necroptosis is a regulated form of necrosis controlled by Receptor-Interacting Protein kinase 1 (RIP1), RIP3, and Mixed Lineage Kinase domain-Like (MLKL), and its role in anticancer therapy remains unclear. TCGA RNAseq data show that RIP3 is significantly downregulated in primary CRC tumors, which is correlated with worse outcomes. RIP3 downregulation also occurs in established CRC cell lines and is associated with decreased 5-FU sensitivity. Therefore, we hypothesize that necroptosis may play a critical role in anticancer therapy and that restoring defective necroptosis may enhance therapeutic sensitivity. Our studies show that RIP3-expressing (RIP3+) CRC cells undergo both apoptosis and necroptosis in response to 5-FU. As expected, knock-out of RIP3 in RIP3+ CRC cells resulted in decreased 5-FU sensitivity, as well as abrogated necroptosis induction. Additionally, stable restoration of RIP3 in RIP3-silenced (RIP3-) CRC cells appeared to enhance 5-FU response, under conditions where apoptosis was inhibited. Furthermore, we explored alternative ways to induce necroptosis in RIP3-silenced cells. Together, our results suggest that necroptosis plays an important role in 5-FU-induced cell death in CRC. These results provide novel insights into the role of necroptosis in anticancer therapy in CRC, which could be used for development of improved therapies and personalized medicine based on RIP3 status. Citation Format: Kaylee Ermine, Dongshi Chen, Xinyan Lu, Jian Yu, Lin Zhang. Targeting defective necroptosis in colorectal cancer to overcome therapeutic resistance [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2534.

oncology
Fig, S3 from RIPK1 Binds MCU to Mediate Induction of Mitochondrial Ca2+ Uptake and Promotes Colorectal Oncogenesis

Fanxin Zeng,Xiao Chen,Weiyi Cui,Wei Wen,Fujian Lu,Xueting Sun,Dongwei Ma,Ye Yuan,Zezhong Li,Ning Hou,Hong Zhao,Xinyu Bi,Jianjun Zhao,Jianguo Zhou,Yan Zhang,Rui-Ping Xiao,Jianqiang Cai,Xiuqin Zhang

DOI: https://doi.org/10.1158/0008-5472.22420607

2023-01-01

Abstract:Figure S3. RIPK3 and p-MLKL is Decreased, while Caspase-8 is Increased in CRC. (A-D) Representative western blots and averaged data of RIPK3, p-MLKL, and Caspase 8 from normal and CRC tissue. Results are expressed as mean {plus minus} SEM. **p < 0.01, normal vs CRC (n=18).
RIP3 promotes colitis-associated colorectal cancer by controlling tumor cell proliferation and CXCL1-induced immune suppression

Zhen-Yu Liu,Ming Zheng,Yi-Ming Li,Xin-Yu Fan,Jian-Chao Wang,Zhu-Chun Li,Hai-Jiao Yang,Jing-Min Yu,Jian Cui,Jian-Li Jiang,Juan Tang,Zhi-Nan Chen

DOI: https://doi.org/10.7150/thno.32126

IF: 11.6

2019-01-01

Theranostics

Abstract:Rationale: Necroptosis is a programmed form of non-apoptotic cell death that requires receptor-interacting protein 3 (RIP3). RIP3 has been shown to be relevant in multiple tumor types and has differential impact on tumor progression. We investigated whether RIP3 is involved in the progression of colitis-associated cancer (CAC) in mice.Methods: Tissues from colorectal cancer patients were examined for RIP3 expression. CAC was induced using azoxymethane (AOM) injection followed by dextran sodium sulfate (DSS) treatment in RIP3-deficient or wild-type mice. Colon tissues were collected and analyzed by Western blotting and gene expression profile analyses. Immune cell infiltration and CXCL1 expression were examined by flow cytometry and Real-time PCR, respectively.Results: RIP3 expression was upregulated in mouse CAC and human colon cancer. RIP3-deficient mice showed significantly attenuated colitis-associated tumorigenesis. Bone marrow transplantation experiments suggested that RIP3's function in hematopoietic cells primarily contributes to the phenotype. RIP3 supported epithelial proliferation and tumor growth via JNK signaling but had no effect on apoptosis. RIP3 deletion increased T cell accumulation and reduced infiltration by immunosuppressive subsets of myeloid cells during acute colitis and CAC. The immune-suppressive tumor microenvironment was dependent on RIP3-induced expression of the chemokine attractant CXCL1, and administration of recombinant CXCL1 during CAC restored tumorigenesis in Rip3-/- mice.Conclusion: Our results reveal an unexpected function of RIP3 in enhancing the proliferation of premalignant intestinal epithelial cells (IECs) and promoting myeloid cell-induced adaptive immune suppression. These two distinct mechanisms of RIP3-induced JNK and CXCL1 signalling contribute to CAC progression.

medicine, research & experimental
RIPK4 driven by TP53 mutations promotes resistance to redox stress of CRC by phosphorylating MTHFD1

Long Yu,Sha Zhou,Yanbo Xu,Zongjin Zhang,Xiaoman Cheng,Chi Zhou,Weihao Li,Jiahua He,Qingjian Ou,Jiayi Qin,Yu-Jing Fang,Jianhong Peng,Jun-Zhong Lin,Bo Lin,Zhenlin Hou,Zhizhong Pan

DOI: https://doi.org/10.1101/2024.08.06.606759

2024-01-01

Abstract:This study investigates advanced colorectal cancer (CRC), focusing on its tendency for distant metastasis and chemotherapy resistance. It highlights the importance of PANoptosis, a cell death pathway, and the role of the Receptor-interacting serine/threonine-protein kinase (RIPK) family in tumor progression. RIPK4's tissue-specific functions in cancer cell behavior are emphasized, including its influence on invasion, migration, and oxidative stress resistance. The study reveals the critical balance of reactive oxygen species (ROS) in cancer cells, linked to antioxidant defenses and NADPH production for survival. A key finding is the connection between TP53 mutations in CRC and increased RIPK4 expression, which enhances MTHFD1 phosphorylation, boosts NADPH production, reduces ROS, and promotes resistance to PANoptosis, leading to metastasis. The research identifies the molecular basis of CRC metastasis, showing how RIPK4 regulates MTHFD1 to resist PANoptosis, offering new therapeutic targets for metastatic CRC and potential improvements in patient outcomes.
PIM3 Functions As Oncogenic Factor and Promotes the Tumor Growth and Metastasis in Colorectal Cancer

Quan Qi,Yuefen Pan,Shuwen Han,Haihong Liao,Yizhen Jiang,Junjun Shen,Liping Zhong,Xian Wang,Jie Chen

DOI: https://doi.org/10.1002/ar.24024

2018-01-01

The Anatomical Record

Abstract:ABSTRACTColorectal cancer (CRC) is one of the common human malignancies. Discovery and identification of novel therapeutic target is imperative to improve the prognosis of CRC patients. As a member of the PIM family, PIM3 has been found to be overexpressed in a variety of cancerous tumors. In this study, we evaluated the expression of PIM3 in CRC tissues and analyzed the role of PIM3 in CRC. Our results showed that PIM3 expression was significantly higher in CRC tissues compared with adjacent noncancerous tissues. The PIM3 expression level was found to be correlated with advanced disease stage and lymph node metastasis. Moreover, PIM3 was found to be able to predict poor prognosis in CRC patients as an independent factor. In vitro studies also showed that knockdown of PIM3 exhibited inhibitory effect on cell growth, promoted cell apoptosis and dampened invasive capability of HCT116 and SW620 cells. Moreover, PIM3 knockdown was able to delay tumor growth and suppress lung metastasis in xenograft model. Our results indicated that PIM3 is a potential therapeutic target for CRC. Anat Rec, 302:1552–1560, 2019. © 2018 American Association for Anatomy
PRMT1 reverts the immune escape of necroptotic colon cancer through RIP3 methylation

Lian Zhang,Yujiao He,Yi Jiang,Qi Wu,Yanchen Liu,Qingqiang Xie,Yuxiu Zou,Jiaqian Wu,Chundong Zhang,Zhongjun Zhou,Xiu-Wu Bian,Guoxiang Jin

DOI: https://doi.org/10.1038/s41419-023-05752-w

2023-04-02

Cell Death and Disease

Abstract:Necroptosis plays a double-edged sword role in necroptotic cancer cell death and tumor immune escape. How cancer orchestrates necroptosis with immune escape and tumor progression remains largely unclear. We found that RIP3, the central activator of necroptosis, was methylated by PRMT1 methyltransferase at the amino acid of RIP3 R486 in human and the conserved amino acid R479 in mouse. The methylation of RIP3 by PRMT1 inhibited the interaction of RIP3 with RIP1 to suppress RIP1-RIP3 necrosome complex, thereby blocking RIP3 phosphorylation and necroptosis activation. Moreover, the methylation-deficiency RIP3 mutant promoted necroptosis, immune escape and colon cancer progression due to increasing tumor infiltrated myeloid-derived immune suppressor cells (MDSC), while PRMT1 reverted the immune escape of RIP3 necroptotic colon cancer. Importantly, we generated a RIP3 R486 di-methylation specific antibody (RIP3 ADMA ). Clinical patient samples analysis revealed that the protein levels of PRMT1 and RIP3 ADMA were positively correlated in cancer tissues and both of them predicted the longer patient survival. Our study provides insights into the molecular mechanism of PRMT1-mediated RIP3 methylation in the regulation of necroptosis and colon cancer immunity, as well as reveals PRMT1 and RIP3 ADMA as the valuable prognosis markers of colon cancer.

cell biology
Supplementary Figure 5 from PPARγ Ligand–induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers

Luxi Chen,Yi Yuan,Shreya Kar,Madhu M. Kanchi,Suruchi Arora,Ji E. Kim,Pei F. Koh,Einas Yousef,Ramar P. Samy,Muthu K. Shanmugam,Tuan Z. Tan,Sung W. Shin,Frank Arfuso,Han M. Shen,Henry Yang,Boon C. Goh,Joo I. Park,Louis Gaboury,Peter E. Lobie,Gautam Sethi,Lina H.K. Lim,Alan P. Kumar

DOI: https://doi.org/10.1158/1535-7163.22509307

2023-01-01

Abstract:Supplementary Figure 5: PPARγ ligand-induced expression of ANXA1 interacts with RIP1 blocking RIP1-NEMO interaction leading to deubiquitination of RIP1.
The BH3-only Protein, PUMA, is Involved in Oxaliplatin-Induced Apoptosis in Colon Cancer Cells

Xinyiny Wang,Ming Li,Jide Wang,Chung-Man Yeung,Hongquan Zhang,Hsiang-fu Kung,Bo Jiang,Marie Chia-mi Lin

DOI: https://doi.org/10.1016/j.bcp.2006.02.011

IF: 6.1

2006-01-01

Biochemical Pharmacology

Abstract:Oxaliplatin, the first line chemotherapeutic of colon cancer, induces damage to tumors via induction of apoptosis. PUMA (p53 up-regulate modulator of apoptosis) is an important pro-apoptotic member of Bcl-2 family and regulated mainly by p53. Here we investigated the role of PUMA in oxalipaltin-induced apoptosis and the potential mechanism. We showed that oxaliplatin-induced PUMA expression in a time- and dose-dependent manner and suppression of PUMA expression by stable transfecting anti-sense PUMA plasmid decreased oxaliplatin-induced apoptosis in colon cancer cells. By abrogating the function of p53, we further demonstrated that the induction was p53-independent. We also found that oxaliplatin could inactivate ERK and suppression of ERK activity by its specific inhibitor (PD98059), and dominant negative plasmid (DN-MEK1) enhanced the oxaliplatin-induced PUMA expression and apoptosis in a p53-independent manner. Taken together, our data suggest that PUMA plays an important role in oxaliplatin-induced apoptosis and the induction could be both p53-dependent and p53-independent. Moreover, PUMA expression and apoptosis in oxaliplatin-treated colon cancer cells could be regulated partly by ERK inactivation. Identification of the molecular components involved in regulating the cellular sensitivity to oxaliplatin may provide potential targets for development of novel compounds that may be useful in enhancement of oxaliplatin cytotoxicity in p53 deficient colon cancer.
Fig, S1 from RIPK1 Binds MCU to Mediate Induction of Mitochondrial Ca2+ Uptake and Promotes Colorectal Oncogenesis

Fanxin Zeng,Xiao Chen,Weiyi Cui,Wei Wen,Fujian Lu,Xueting Sun,Dongwei Ma,Ye Yuan,Zezhong Li,Ning Hou,Hong Zhao,Xinyu Bi,Jianjun Zhao,Jianguo Zhou,Yan Zhang,Rui-Ping Xiao,Jianqiang Cai,Xiuqin Zhang

DOI: https://doi.org/10.1158/0008-5472.22420613.v1

2023-01-01

Abstract:Figure S1. High levels of RIPK1 Expression shows Poor Prognosis. (A) Relative levels of RIPK1 expression in CRC on different tumor stages (n = 40). (B) Relative levels of RIPK1 expression between alive (n=30) and death (n=8) in CRC.
Supplementary Fig.4 from Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor

Tingyu Wu,Wei Chen,Yongwang Zhong,Xiaodan Hou,Shengyun Fang,Chen-Ying Liu,Guanghui Wang,Tong Yu,Yu-Yang Huang,Xuesong Ouyang,Henry Q.X. Li,Long Cui,Yili Yang

DOI: https://doi.org/10.1158/1535-7163.22507974.v1

2023-01-01

Abstract:Nuclear p53 plays a critical role in synergistic cytotoxic effect in RKO cells.
Differential Roles of RIPK1 and RIPK3 in TNF-induced Necroptosis and Chemotherapeutic Agent-Induced Cell Death.

K Moriwaki,J Bertin,P J Gough,G M Orlowski,F KM Chan

DOI: https://doi.org/10.1038/cddis.2015.16

2015-01-01

Cell Death and Disease

Abstract:Apoptosis is a key mechanism for metazoans to eliminate unwanted cells. Resistance to apoptosis is a hallmark of many cancer cells and a major roadblock to traditional chemotherapy. Recent evidence indicates that inhibition of caspase-dependent apoptosis sensitizes many cancer cells to a form of non-apoptotic cell death termed necroptosis. This has led to widespread interest in exploring necroptosis as an alternative strategy for anti-cancer therapy. Here we show that in human colon cancer tissues, the expression of the essential necroptosis adaptors receptor interacting protein kinase (RIPK)1 and RIPK3 is significantly decreased compared with adjacent normal colon tissues. The expression of RIPK1 and RIPK3 was suppressed by hypoxia, but not by epigenetic DNA modification. To explore the role of necroptosis in chemotherapy-induced cell death, we used inhibitors of RIPK1 or RIPK3 kinase activity, and modulated their expression in colon cancer cell lines using short hairpin RNAs. We found that RIPK1 and RIPK3 were largely dispensable for classical chemotherapy-induced cell death. Caspase inhibitor and/or second mitochondria-derived activator of caspase mimetic, which sensitize cells to RIPK1- and RIPK3-dependent necroptosis downstream of tumor necrosis factor receptor-like death receptors, also did not alter the response of cancer cells to chemotherapeutic agents. In contrast to the RIPKs, we found that cathepsins are partially responsible for doxorubicin or etoposide-induced cell death. Taken together, these results indicate that traditional chemotherapeutic agents are not efficient inducers of necroptosis and that more potent pathway-specific drugs are required to fully harness the power of necroptosis in anti-cancer therapy.
RIP3 regulates doxorubicin-induced intestinal mucositis via FUT2-mediated α-1,2-fucosylation

Wei Wen,Xiaomin Hu,Jialin Liu,Fanxin Zeng,Yihua Xu,Ye Yuan,Chunyan Gao,Xueting Sun,Bo Cheng,Jue Wang,Xinli Hu,Rui-Ping Xiao,Xing Chen,Xiuqin Zhang

DOI: https://doi.org/10.1007/s00011-024-01932-2

2024-08-24

Abstract:Objective: Intestinal mucositis is one of the common side effects of anti-cancer chemotherapy. However, the molecular mechanisms involved in mucositis development remain incompletely understood. In this study, we investigated the function of receptor-interacting protein kinase 3 (RIP3/RIPK3) in regulating doxorubicin-induced intestinal mucositis and its potential mechanisms. Methods: Intestinal mucositis animal models were induced in mice for in vivo studies. Rat intestinal cell line IEC-6 was used for in vitro studies. RNA‑seq was used to explore the transcriptomic changes in doxorubicin-induced intestinal mucositis. Intact glycopeptide characterization using mass spectrometry was applied to identify α-1,2-fucosylated proteins associated with mucositis. Results: Doxorubicin treatment increased RIP3 expression in the intestine and caused severe intestinal mucositis in the mice, depletion of RIP3 abolished doxorubicin-induced intestinal mucositis. RIP3-mediated doxorubicin-induced mucositis did not depend on mixed lineage kinase domain-like (MLKL) but on α-1,2-fucosyltransferase 2 (FUT2)-catalyzed α-1,2-fucosylation on inflammation-related proteins. Deficiency of MLKL did not affect intestinal mucositis, whereas inhibition of α-1,2-fucosylation by 2-deoxy-D-galactose (2dGal) profoundly attenuated doxorubicin-induced inflammation and mucositis. Conclusions: RIP3-FUT2 pathway is a central node in doxorubicin-induced intestinal mucositis. Targeting intestinal RIP3 and/or FUT2-mediated α-1,2-fucosylation may provide potential targets for preventing chemotherapy-induced intestinal mucositis.
RIPK3 activation induces TRIM28 derepression in cancer cells and enhances the anti-tumor microenvironment

Han-Hee Park,Hwa-Ryeon Kim,Sang-Yeong Park,Sung-Min Hwang,Sun Mi Hong,Sangwook Park,Ho Chul Kang,Michael J. Morgan,Jong-Ho Cha,Dakeun Lee,Jae-Seok Roe,You-Sun Kim

DOI: https://doi.org/10.1186/s12943-021-01399-3

IF: 37.3

2021-08-21

Molecular Cancer

Abstract:Abstract Background Necroptosis is emerging as a new target for cancer immunotherapy as it is now recognized as a form of cell death that increases tumor immunogenicity, which would be especially helpful in treating immune-desert tumors. De novo synthesis of inflammatory proteins during necroptosis appears especially important in facilitating increased anti-tumor immune responses. While late-stage transcription mediated by NF-κB during cell death is believed to play a role in this process, it is otherwise unclear what cell signaling events initiate this transactivation of inflammatory genes. Methods We employed tandem-affinity purification linked to mass spectrometry (TAP-MS), in combination with the analysis of RNA-sequencing (RNA-Seq) datasets to identify the Tripartite Motif Protein 28 (TRIM28) as a candidate co-repressor. Comprehensive biochemical and molecular biology techniques were used to characterize the role of TRIM28 in RIPK3 activation-induced transcriptional and immunomodulatory events. The cell composition estimation module was used to evaluate the correlation between RIPK3/TRIM28 levels and CD8 + T cells or dendritic cells (DC) in all TCGA tumors. Results We identified TRIM28 as a co-repressor that regulates transcriptional activity during necroptosis. Activated RIPK3 phosphorylates TRIM28 on serine 473, inhibiting its chromatin binding activity, thereby contributing to the transactivation of NF-κB and other transcription factors, such as SOX9. This leads to elevated cytokine expression, which then potentiates immunoregulatory processes, such as DC maturation. The expression of RIPK3 has a significant positive association with the tumor-infiltrating immune cells populations in various tumor type, thereby activating anti-cancer responses. Conclusion Our data suggest that RIPK3 activation-dependent derepression of TRIM28 in cancer cells leads to increased immunostimulatory cytokine production in the tumor microenvironment, which then contributes to robust cytotoxic anti-tumor immunity.

oncology,biochemistry & molecular biology

Figure S3 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Figure S4 from PUMA/RIP3 Mediates Chemotherapy Response via Necroptosis and Local Immune Activation in Colorectal Cancer

Figure S8 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Figure S5 from PUMA/RIP3 Mediates Chemotherapy Response via Necroptosis and Local Immune Activation in Colorectal Cancer

Figure S1 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Figure S2 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Table S1 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Table S2 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Abstract 2534: Targeting defective necroptosis in colorectal cancer to overcome therapeutic resistance

Fig, S3 from RIPK1 Binds MCU to Mediate Induction of Mitochondrial Ca2+ Uptake and Promotes Colorectal Oncogenesis

RIP3 promotes colitis-associated colorectal cancer by controlling tumor cell proliferation and CXCL1-induced immune suppression

RIPK4 driven by TP53 mutations promotes resistance to redox stress of CRC by phosphorylating MTHFD1

PIM3 Functions As Oncogenic Factor and Promotes the Tumor Growth and Metastasis in Colorectal Cancer

PRMT1 reverts the immune escape of necroptotic colon cancer through RIP3 methylation

Supplementary Figure 5 from PPARγ Ligand–induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers

The BH3-only Protein, PUMA, is Involved in Oxaliplatin-Induced Apoptosis in Colon Cancer Cells

Fig, S1 from RIPK1 Binds MCU to Mediate Induction of Mitochondrial Ca&lt;sup&gt;2+&lt;/sup&gt; Uptake and Promotes Colorectal Oncogenesis

Supplementary Fig.4 from Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor

Differential Roles of RIPK1 and RIPK3 in TNF-induced Necroptosis and Chemotherapeutic Agent-Induced Cell Death.

RIP3 regulates doxorubicin-induced intestinal mucositis via FUT2-mediated α-1,2-fucosylation

RIPK3 activation induces TRIM28 derepression in cancer cells and enhances the anti-tumor microenvironment

Fig, S1 from RIPK1 Binds MCU to Mediate Induction of Mitochondrial Ca<sup>2+</sup> Uptake and Promotes Colorectal Oncogenesis